Compare TSN & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSN | MEDP |
|---|---|---|
| Founded | 1935 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2B | 16.6B |
| IPO Year | 1994 | 2016 |
| Metric | TSN | MEDP |
|---|---|---|
| Price | $52.19 | $622.73 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 12 |
| Target Price | $66.90 | ★ $473.17 |
| AVG Volume (30 Days) | ★ 3.0M | 172.6K |
| Earning Date | 05-04-2026 | 04-22-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | 1.49 | ★ 8.53 |
| Revenue | ★ $54,441,000,000.00 | N/A |
| Revenue This Year | $5.74 | $13.19 |
| Revenue Next Year | $1.14 | $7.75 |
| P/E Ratio | ★ $35.53 | $72.09 |
| Revenue Growth | ★ 2.12 | N/A |
| 52 Week Low | $50.56 | $373.00 |
| 52 Week High | $69.48 | $677.90 |
| Indicator | TSN | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 37.99 | 63.83 |
| Support Level | $50.71 | $575.89 |
| Resistance Level | $59.81 | $629.30 |
| Average True Range (ATR) | 1.21 | 13.17 |
| MACD | 0.04 | 1.74 |
| Stochastic Oscillator | 27.02 | 94.08 |
Tyson Foods is a protein-focused food producer, selling raw chicken, beef, pork, and prepared foods. Chicken and beef are its two largest segments, composing about 40% and 30% of sales, respectively. Prepared foods constituted 18% of fiscal 2025 sales and include brands like Tyson, Jimmy Dean, Hillshire Farm, Ball Park, and Sara Lee. However, most of these are in product categories rife with competition where Tyson does not have a massive market share lead. Tyson sells some products overseas, but the international segment accounts for just 4% of total revenue. The company is an active acquirer, with more recent years' purchases focused on international and food-service markets.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.